Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.82 HKD | -1.20% | 0.00% | -10.87% |
Apr. 30 | LH Group Limited Announces Board and Committee Changes | CI |
Apr. 29 | Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 464 | 396 | 376 | 840 | 856 | 736 |
Enterprise Value (EV) 1 | 173.7 | 421.5 | 226.4 | 693.9 | 737.7 | 738.5 |
P/E ratio | 11.8 x | -35.3 x | 2.68 x | 9.33 x | 11 x | 8.36 x |
Yield | 9.31% | 10% | 28% | 8.05% | 7.26% | 9.58% |
Capitalization / Revenue | 0.46 x | 0.39 x | 0.47 x | 0.84 x | 0.8 x | 0.57 x |
EV / Revenue | 0.17 x | 0.42 x | 0.28 x | 0.69 x | 0.69 x | 0.58 x |
EV / EBITDA | 1.64 x | 3.75 x | 4.93 x | 5.89 x | 8.57 x | 4.82 x |
EV / FCF | 4.29 x | 2.25 x | 3.37 x | 3.71 x | 5.91 x | 3.56 x |
FCF Yield | 23.3% | 44.5% | 29.7% | 27% | 16.9% | 28.1% |
Price to Book | 1.13 x | 1.44 x | 0.91 x | 2.21 x | 2.09 x | 2.47 x |
Nbr of stocks (in thousands) | 800,000 | 800,000 | 800,000 | 800,000 | 800,000 | 800,000 |
Reference price 2 | 0.5800 | 0.4950 | 0.4700 | 1.050 | 1.070 | 0.9200 |
Announcement Date | 4/29/19 | 4/29/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 1,007 | 1,010 | 806 | 1,003 | 1,067 | 1,280 |
EBITDA 1 | 105.7 | 112.4 | 45.88 | 117.9 | 86.13 | 153.1 |
EBIT 1 | 55.09 | 68.14 | 13.05 | 84.16 | 45.62 | 115.5 |
Operating Margin | 5.47% | 6.75% | 1.62% | 8.39% | 4.28% | 9.02% |
Earnings before Tax (EBT) 1 | 43.74 | -0.948 | 143.7 | 103.1 | 84.44 | 104.4 |
Net income 1 | 35.21 | -11.23 | 140.3 | 90.08 | 77.7 | 88.06 |
Net margin | 3.5% | -1.11% | 17.41% | 8.98% | 7.28% | 6.88% |
EPS 2 | 0.0490 | -0.0140 | 0.1754 | 0.1126 | 0.0971 | 0.1101 |
Free Cash Flow 1 | 40.51 | 187.4 | 67.25 | 187.1 | 124.7 | 207.3 |
FCF margin | 4.02% | 18.56% | 8.34% | 18.64% | 11.69% | 16.2% |
FCF Conversion (EBITDA) | 38.31% | 166.8% | 146.6% | 158.73% | 144.84% | 135.46% |
FCF Conversion (Net income) | 115.05% | - | 47.93% | 207.71% | 160.54% | 235.43% |
Dividend per Share 2 | 0.0540 | 0.0496 | 0.1316 | 0.0845 | 0.0777 | 0.0881 |
Announcement Date | 4/29/19 | 4/29/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 25.5 | - | - | - | 2.46 |
Net Cash position 1 | 290 | - | 150 | 146 | 118 | - |
Leverage (Debt/EBITDA) | - | 0.2266 x | - | - | - | 0.0161 x |
Free Cash Flow 1 | 40.5 | 187 | 67.3 | 187 | 125 | 207 |
ROE (net income / shareholders' equity) | 11.5% | -3.29% | 40.7% | 22.7% | 19.7% | 24.9% |
ROA (Net income/ Total Assets) | 7.48% | 6.47% | 1.1% | 6.87% | 3.5% | 8.99% |
Assets 1 | 470.8 | -173.4 | 12,812 | 1,311 | 2,222 | 979.6 |
Book Value Per Share 2 | 0.5100 | 0.3400 | 0.5200 | 0.4800 | 0.5100 | 0.3700 |
Cash Flow per Share 2 | 0.1800 | 0.1600 | 0.2200 | 0.3000 | 0.2500 | 0.1800 |
Capex 1 | 55.1 | 35.4 | 18.4 | 42.3 | 37 | 20.1 |
Capex / Sales | 5.47% | 3.5% | 2.28% | 4.21% | 3.46% | 1.57% |
Announcement Date | 4/29/19 | 4/29/20 | 4/29/21 | 4/28/22 | 4/28/23 | 4/26/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-10.87% | 84.99M | |
+35.42% | 11.06B | |
+18.51% | 8.76B | |
+8.35% | 2.28B | |
-13.03% | 2.01B | |
+11.77% | 1.99B | |
+11.61% | 1.8B | |
-0.37% | 1.47B | |
-17.15% | 903M | |
-2.64% | 820M |
- Stock Market
- Equities
- 1978 Stock
- Financials LH Group Limited